Formulation Development
BIOSIMILAR DEVELOPMENT - Guidance on Biosimilar Interchangeability: The Debate Over Drug Delivery Devices
Darren Mansell says as early experience in following this guidance has recently matured, some issues have arisen that may impede best available outcomes for patients, one of which is the question of whether “interchangeability” guidance may stifle innovation (and therefore improved patient experience) in drug delivery devices.
OPEN INNOVATION PLATFORM - Incentivizing Drug Delivery Research Using an Open Sharing Platform
Keith R. Horspool, PhD, Shirlynn Chen, PhD, and Markus Koester, PhD, discuss an open innovation platform to stimulate scientific understanding, and development of potential new technologies, for delivery of compounds with challenging solubility by offering a set of more contemporary poorly soluble drugs free-of-charge for independent research activities.
EXECUTIVE INTERVIEW - Celanese: Better Therapeutic Outcomes From Better Drug Delivery
Laura Brand, Vice President of Celanese’s Medical & Pharmaceutical Business, discusses her company’s drug delivery platform and the value it brings to the industry.
NUCLEAR β-CATENIN INHIBITOR - TBL1 - A Novel Target for Safe & Effective Blockade of the Nuclear β-catenin Signaling Pathway
Ruolan Han, PhD, explains how targeting TBL1/TBLR1 enables specific silencing of oncogenic Wnt target gene expression without affecting other necessary cellular functions that are disrupted when targeting higher up the Wnt pathway.
EXECUTIVE INTERVIEW - SDP Oncology: Uncovering New Biology
David J. Bearss, PhD, Chief Scientific Officer and Global Head of Research at SDP Oncology, discusses his company’s unique structure that has supported its robust research in the tumor immune microenvironment as well as its investigational assets being studied in this space.
Clinical Trial Data on the Use of Probiotics in Outpatients With COVID-19
Researchers at the Hospital General Manuel Gea González in Mexico City have reported results from a study designed to assess the impact of four specific strains of probiotics on the rate of remission from infection with SARS-CoV-2….
Agios Shareholders Approve Sale of Oncology Business to Servier
Agios Pharmaceuticals, Inc. recently announced its shareholders voted to approve the previously disclosed sale of its commercial, clinical, and research-stage oncology portfolio to….
CureVac’s COVID-19 Vaccine Candidate Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant in Preclinical Challenge Study
CureVac N.V. recently announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of…
Dunad Therapeutics Emerges to Develop Next-Generation Small Molecule Therapeutics Based on First Tuneable Targeted Protein Degradation Technology
Dunad Therapeutics recently emerged to develop next-generation small molecule therapeutics based on its highly differentiated, tuneable, and targeted protein degradation technology. Dunad, secured initial financing…
Visus Therapeutics Initiates Phase 2 Clinical Trial for Presbyopia Treatment
Visus Therapeutics Inc. recently announced the commencement of its Phase 2 clinical trial of BRIMOCHOL topical ophthalmic solution under investigation for the treatment of presbyopia.…
AstraZeneca’s & J&J’s COVID-19 Vaccines Manufacturing Face Viral Vector Shortages
The latest wave of COVID-19 vaccines - those from AstraZeneca and Johnson & Johnson (J&J) - are recombinant vector vaccines, which are a different molecule…
Catalent Signs Drug Development Agreement With Cybin Inc
Catalent recently announced it has signed an agreement with Cybin Inc. to apply Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology for the delivery of…
IONTAS Identifies Novel SARS-CoV-2 Neutralizing Antibodies
IONTAS Limited and FairJourney Biologics S.A recently announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a…
Micropore Appoints Technology Distributor for Japanese Market
Award-winning UK-based particle engineering specialist Micropore Technologies has just announced the appointment of the Mutual Corporation as the representative for sales….
Hovione Completes its Phase 2 Clinical Trial of the First Minocycline Ophthalmic
Hovione recently announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused….
Axol Bioscience & Censo Biotechnologies Announce Merger
Axol Bioscience Ltd and CENSO Biotechnologies recently announced that the two companies have signed a merger agreement. The new entity will become a leading provider…
ProBioGen Licenses GlymaxX Technology to Sanofi
ProBioGen AG has recently signed a commercial multi-product license agreement with Sanofi. Under such agreement, Sanofi will integrate ProBioGen’s proprietary GlymaxX technology into their product development…
Timber Pharmaceuticals Announces 50% Enrollment in Phase 2b CONTROL Study
Timber Pharmaceuticals, Inc. recently announced 50% of patients in the Phase 2b CONTROL study evaluating TMB-001 (topical isotretinoin) in patients with moderate-to-severe congenital ichthyosis (CI)…
FSD Pharma Enters License Agreement to Develop FDA-Approved Veterinary Drugs
FSD Pharma recently announced it has entered into a license agreement with Innovet Italia S.R.L., under which Innovet granted the company a license to use…
AC Immune Announces New Clinical Results in Down Syndrome, Plans for Future Development of Anti-Amyloid-Beta Vaccine
AC Immune SA recently announced plans to advance its novel anti-amyloid-beta (Abeta) vaccine into mid-stage clinical testing to treat and prevent the progression of Down…
